ISOPAQUE 440
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISOPAQUE 440 is an injectable diagnostic agent approved in 1973 by GE HealthCare. The specific mechanism of action and clinical indications are not publicly detailed in available data, but the injection route and diagnostic classification suggest it is a contrast or imaging agent. This is a legacy product with significant historical clinical use.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial team is likely focused on transition planning and defending market share against generic/biosimilar entrants.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ISOPAQUE 440 offers limited growth trajectory but provides deep expertise in late-lifecycle product management, payer relations, and cost-control strategies. This role is best suited for professionals seeking to develop transition management and market defense skills in a mature pharmaceutical asset.
Brand ManagerProduct Manager
Worked on ISOPAQUE 440 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.